HC Wainwright maintains "Buy" rating for Altimmune (ALT) at $12.00 despite negative ROE and net margin.

HC Wainwright reaffirms "Buy" rating for Altimmune (ALT) at $12.00, despite negative ROE and net margin in recent earnings report. Altimmune's lead product candidate, pemvidutide, is in Phase 2 trials for obesity and metabolic dysfunction-associated steatohepatitis, with an average analyst target price of $18.80. The company faces challenges in terms of low market cap and beta, along with mixed insider transactions; however, multiple analysts remain positive about the stock.